cas 1353745-17-1|| where to buy Di-tert-butyl 1-ethynylhydrazine-1,2-dicarboxylate

Nom du produit:Di-tert-butyl 1-ethynylhydrazine-1,2-dicarboxylate

IUPAC Name:N'-[(tert-butoxy)carbonyl]-N-ethynyl(tert-butoxy)carbohydrazide

Unité d'emballage	Stock disponible	Prix($)	Quantité

Pour une utilisation en R&D uniquement..

Formulaire de demande

Nom chimique

Numéro CAS

Quantité*

Spécifications requises*
(% d'analyse, qualité du matériau, etc.)

Nom du contact*

Email du contact*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1353745-17-1 regularly via the above email.

Notes supplémentaires

Verification code*

refresh

: N° CAS:1353745-17-1; Formule moléculaire:C12H20N2O4; Point de fusion:-; Code SMILES:O=C(N(C#C)NC(OC(C)(C)C)=O)OC(C)(C)C; Densité:

: Numéro de catalogue:CM1075334; Poids moléculaire:256.3; Point d'ébullition:; N° Mdl:; Stockage:

: Aliphatic Chain Compounds; Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

: INX-315; Incyclix Bio announces FDA clearance of investigational new drug application for INX-315 in patients with advanced or metastatic cancer. INX-315 is a novel, potent and selective inhibitor of Cyclin-dependent kinase 2 (CDK2) with compelling pre-clinical efficacy and safety data.
CDK2 is thought to play an important role in driving proliferation of certain cancers, including those harboring CCNE1 amplification and breast cancers that have acquired resistance to CDK4/6 inhibitors (CDK4/6i).